Pfizer’s possible offer for AstraZeneca plc represents compelling shareholder value
13 May 2014 | By Pfizer
Pfizer is publishing a presentation to the shareholders of AstraZeneca on the merits of a combination of the two companies...
List view / Grid view
News
TSI completes Drug Master File for the BioTrak® Real-Time Viable Particle Counter
12 May 2014 | By TSI
TSI Incorporated, the premier provider of particle counting solutions for life science applications, is pleased to announce the submission of a Type V Drug Master File...
Field Based Chemistry North America and Europe
12 May 2014 | By kdm communications
Cresset, innovative provider of computational chemistry software and services, announces its annual user meetings, ‘Field Based Chemistry North America’ and ‘Field Based Chemistry Europe’...
Announcement regarding the post-evaluation result for the project of H5N1 influenza vaccine
12 May 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced in August 2011 that the Group company, Kitasato Daiichi Sankyo Vaccine Company Limited, had been selected for the Japanese Ministry of Health, Labour and Welfare’s cell culture vaccine production facility capacity building grant...
NovoEight® provides long-term reduction of bleeding in people with haemophilia A
12 May 2014 | By Novo Nordisk
Novo Nordisk announced new phase 3 interim data from its guardian™2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade...
FDA approves ZONTIVITY™, first-in-class PAR-1 antagonist, for the reduction of thrombotic cardiovascular events in patients with a history of heart attack or with peripheral arterial disease
12 May 2014 | By Merck
ZONTIVITY added to standard of care demonstrated long-term benefit through three years...
Richard A. Rudick joins Biogen Idec as Vice President, Development Sciences, Value-Based Medicine
12 May 2014 | By Biogen Idec
Biogen Idec announced that Richard (Rick) A. Rudick, M.D., has joined the company as vice president, Development Sciences, Value-Based Medicine...
Amgen and AstraZeneca announce positive results from Phase III study of brodalumab (AMG 827) in patients with moderate-to-severe plaque psoriasis
12 May 2014 | By AstraZeneca
Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints...
Promising preliminary data show Abbott’s innovative testing platform may identify life-threatening infections faster than current methods
12 May 2014 | By Abbott
Early study results suggest Abbott technology equivalent to current standard of care, but produces results much more quickly...
The publishers of European Pharmaceutical Review launch new magazine aimed at the drug discovery industry
12 May 2014 | By European Pharmaceutical Review
European Drug Target Review is a business-to-business magazine featuring the latest developments in drug discovery and new drug development collaborations...
New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients
8 May 2014 | By Boehringer Ingelheim
Details of a new 6,000 patient study of dabigatran etexilate were announced at the European Stroke Conference, Nice, France...
AbbVie submits for EU marketing authorization its investigational, all-oral, interferon-free therapy for the treatment of chronic hepatitis C
8 May 2014 | By AbbVie
AbbVie submitted marketing authorization applications to the European Medicines Agency seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus infection...
Janssen submits supplemental New Drug Application to U.S. FDA for OLYSIO™ for once-daily use in combination with Sofosbuvir for 12 weeks for the treatment of adult patients with genotype 1 chronic hepatitis C
8 May 2014 | By Johnson & Johnson
Filing Includes data from treatment-naïve patients with advanced fibrosis and null responders with all stages of liver fibrosis...
Quotient Clinical extends its Translational Pharmaceutics™ platform into cancer drug development
7 May 2014 | By kdm communications
Quotient Clinical has announced the extension of its Translational Pharmaceutics™ platform into patient-focused cancer drug development...
Study found INVEGA® SUSTENNA® once-monthly long-acting therapy delayed time to and reduced risk of relapse in individuals with schizoaffective disorder as monotherapy and adjunctive therapy
7 May 2014 | By Johnson & Johnson
Demonstrated significant efficacy in manic and depressive mood symptoms and psychosis, and improved patient functioning...
